Hatzis-Schoch Brent 4

What Happened Brent Hatzis‑Schoch, Chief Operating Officer and General Counsel of Black Diamond Therapeutics (BDTX), received a derivative award on January 21, 2026 covering 250,000 shares. The Form 4 reports the award as a derivative grant (code A) with an acquisition price listed as $0.00. This was a grant of options rather than an open-market purchase or sale.

Key Details

• Transaction date: January 21, 2026; Form 4 filed January 23, 2026 (appears timely under Form 4 rules).
• Grant: 250,000-share option award (reported as derivative, acquisition price $0.00).
• Vesting (footnote): 25% vests on January 21, 2027; the remainder vests in 36 equal monthly installments thereafter, subject to continued service.
• Shares owned after the transaction: Not specified in the filing.
• Filing remarks confirm the insider’s title: Chief Operating Officer and General Counsel.

Context This transaction is an equity compensation grant (option award) common for executives and does not represent a market purchase or sale. Vesting is time‑based, so the award only becomes exercisable over the coming years if the reporting person remains employed. There is no indication of an immediate sale or cashless exercise in this filing.